Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
10/23/17 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares Read More »
Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering Read More »
Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress Read More »